Dai­ichi Sankyo scores first nod for IV iron re­place­ment drug in pa­tients with heart fail­ure

Dai­ichi Sankyo is ex­pand­ing the la­bel of its iron re­place­ment in­jectable, In­jectafer, in­to a first-of-its-kind in­di­ca­tion, ac­cord­ing to the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.